179 related articles for article (PubMed ID: 35251346)
1. Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence.
Christopoulou A; Ardavanis A; Papandreou C; Koumakis G; Papatsimpas G; Papakotoulas P; Tsoukalas N; Andreadis C; Samelis G; Papakostas P; Aravantinos G; Ziras N; Souggleri M; Kalofonos C; Samantas E; Makrantonakis P; Pentheroudakis G; Athanasiadis A; Stergiou H; Bokas A; Grivas A; Tripodaki ES; Varthalitis I; Timotheadou E; Boukovinas I
Oncol Lett; 2022 Apr; 23(4):115. PubMed ID: 35251346
[TBL] [Abstract][Full Text] [Related]
2. Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study.
Xynogalos S; Simeonidis D; Papageorgiou G; Pouliakis A; Charalambakis N; Lianos E; Mazlimoglou E; Liatsos AN; Kosmas C; Ziras N
Support Care Cancer; 2022 Aug; 30(8):6973-6984. PubMed ID: 35552827
[TBL] [Abstract][Full Text] [Related]
3. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
Jonmarker S; Hollenberg J; Dahlberg M; Stackelberg O; Litorell J; Everhov ÅH; Järnbert-Pettersson H; Söderberg M; Grip J; Schandl A; Günther M; Cronhjort M
Crit Care; 2020 Nov; 24(1):653. PubMed ID: 33225952
[TBL] [Abstract][Full Text] [Related]
4. Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study.
Akinosoglou K; Savopoulos C; Pouliakis A; Triantafyllidis C; Markatis E; Golemi F; Liontos A; Vadala C; Papanikolaou IC; Dimakopoulou V; Xarras P; Varela K; Kaiafa G; Mitsianis A; Chatzistamati A; Randou E; Savvanis S; Pavlaki M; Efraimidis G; Samaras V; Papazoglou D; Konstantinidou A; Panagopoulos P; Milionis H; On Behalf Of The Interact Study Group
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458497
[TBL] [Abstract][Full Text] [Related]
5. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
Bara L; Planes A; Samama MM
Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study.
Norris LA; Bonnar J; Smith MP; Steer PJ; Savidge G
Thromb Haemost; 2004 Oct; 92(4):791-6. PubMed ID: 15467910
[TBL] [Abstract][Full Text] [Related]
7. Extended thromboprophylaxis post gynaecological cancer surgery; the effect of weight adjusted and fixed dose LMWH (Tinzaparin).
Abu Saadeh F; Marchocki Z; O'Toole SA; Ibrahim N; Gleeson N; Norris LA
Thromb Res; 2021 Nov; 207():25-32. PubMed ID: 34530386
[TBL] [Abstract][Full Text] [Related]
8. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy.
Ní Ainle F; Wong A; Appleby N; Byrne B; Regan C; Hassan T; Milner M; Sullivan AO; White B; O'Donnell J
Blood Coagul Fibrinolysis; 2008 Oct; 19(7):689-92. PubMed ID: 18832911
[TBL] [Abstract][Full Text] [Related]
10. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
11. Tinzaparin in intermediate dose for the treatment of superficial vein thrombosis: Results from an observational multicenter study-SeVEN study.
Giannoukas A; Karathanos C; Nikolakopoulos K; Georgiadis GS; Maltezos C; Ioannou C; Vasdekis S; Trelopoulos G;
Phlebology; 2018 Oct; 33(9):636-645. PubMed ID: 29277133
[TBL] [Abstract][Full Text] [Related]
12. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
Siguret V; Pautas E; Février M; Wipff C; Durand-Gasselin B; Laurent M; Andreux JP; d'Urso M; Gaussem P
Thromb Haemost; 2000 Nov; 84(5):800-4. PubMed ID: 11127859
[TBL] [Abstract][Full Text] [Related]
13. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
Lee AY; Bauersachs R; Janas MS; Jarner MF; Kamphuisen PW; Meyer G; Khorana AA;
BMC Cancer; 2013 Jun; 13():284. PubMed ID: 23764005
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Tinzaparin Thromboprophylaxis in Lung Cancer Patients with High Thromboembolic Risk: A Prospective, Observational, Single-Center Cohort Study.
Kouvela M; Livanou ME; Stefanou DT; Vathiotis IA; Sarropoulou F; Grammoustianou M; Dimakakos E; Syrigos N
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611118
[TBL] [Abstract][Full Text] [Related]
15. PO-34 - Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor.
Panicot-Dubois L; Mezouar S; Plantureux L; Crescence L; Frère C; Dubois C
Thromb Res; 2016 Apr; 140 Suppl 1():S189. PubMed ID: 27161722
[TBL] [Abstract][Full Text] [Related]
16. Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients.
Pfrepper C; Koch E; Weise M; Siegemund R; Siegemund A; Petros S; Metze M
Res Pract Thromb Haemost; 2023 Feb; 7(2):100054. PubMed ID: 36876282
[TBL] [Abstract][Full Text] [Related]
17. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
Cheer SM; Dunn CJ; Foster R
Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study.
Karamouzis MV; Athanasiadis I; Samelis G; Vallilas C; Bokas A; Nikolaidi A; Dimitriadou A; Sarantis P; Pistamaltzian N; Schizas D; Papalampros A; Felekouras E; Dimitroulis D; Antoniou E; Sotiropoulos G; Papakotoulas P
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207591
[TBL] [Abstract][Full Text] [Related]
19. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy.
Smith MP; Norris LA; Steer PJ; Savidge GF; Bonnar J
Am J Obstet Gynecol; 2004 Feb; 190(2):495-501. PubMed ID: 14981396
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
